Vijapurkar U - Search Results

1

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Kramer M, et al. Among authors: vijapurkar u. J Clin Psychopharmacol. 2007 Feb;27(1):6-14. doi: 10.1097/JCP.0b013e31802dda4a. J Clin Psychopharmacol. 2007. PMID: 17224706 Clinical Trial.

2

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. Gopal S, et al. Among authors: vijapurkar u. J Psychopharmacol. 2011 May;25(5):685-97. doi: 10.1177/0269881110372817. Epub 2010 Jul 8. J Psychopharmacol. 2011. PMID: 20615933 Clinical Trial.

3

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Hough D, et al. Among authors: vijapurkar u. Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2. Schizophr Res. 2010. PMID: 19959339 Clinical Trial.

4

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.

Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. Singh J, et al. Among authors: vijapurkar u. Biol Psychiatry. 2011 Dec 15;70(12):1179-87. doi: 10.1016/j.biopsych.2011.06.021. Epub 2011 Aug 9. Biol Psychiatry. 2011. PMID: 21831359 Clinical Trial.

5

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.

Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Davies MJ, et al. Among authors: vijapurkar u. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7. Cardiovasc Diabetol. 2017. PMID: 28327140 Free PMC article. Clinical Trial.

6

Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L. Bailey RA, et al. Among authors: vijapurkar u. Am J Manag Care. 2014 Dec;20(13 Suppl):s296-305. Am J Manag Care. 2014. PMID: 25734218 Free article. Clinical Trial.

7

Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.

Davidson JA, Aguilar R, Lavalle González FJ, Trujillo A, Alba M, Vijapurkar U, Meininger G. Davidson JA, et al. Among authors: vijapurkar u. Ethn Dis. 2016 Apr 21;26(2):221-8. doi: 10.18865/ed.26.2.221. Ethn Dis. 2016. PMID: 27103773 Free PMC article.

8

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.

Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Pfeifer M, et al. Among authors: vijapurkar u. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0. Cardiovasc Diabetol. 2017. PMID: 28241822 Free PMC article. Clinical Trial.

9

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.

Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L. Patel CA, et al. Among authors: vijapurkar u. BMC Health Serv Res. 2016 Aug 5;16(a):356. doi: 10.1186/s12913-016-1607-z. BMC Health Serv Res. 2016. PMID: 27495291 Free PMC article.

10

Bailey RA, Vijapurkar U, Meininger G, Rupnow MF, Blonde L. Bailey RA, et al. Among authors: vijapurkar u. Clin Ther. 2015 May 1;37(5):1045-54. doi: 10.1016/j.clinthera.2015.02.020. Epub 2015 Mar 18. Clin Ther. 2015. PMID: 25795432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters